Vitiligo

Explore the promising role of JAK inhibitors in vitiligo management, highlighting efficacy, safety, and potential combination therapies for enhanced results.

Genetic proxies for PCSK9 inhibition were consistently associated with reduced vitiligo risk across 2 biobanks.

Phototherapy, commonly used for vitiligo, might help reduce cardiovascular risk through anti-inflammatory effects.

Corticosteroids, calcineurin inhibitors, and fractional CO2 laser were also effective in achieving high levels of repigmentation.

The significance of patient education and setting realistic expectations for the often-slow process of repigmentation in vitiligo treatment was a key focus of the discussion.

Compared to patients with rheumatoid arthritis and atopic dermatitis, those with vitiligo had a lower incidence of major adverse effects.

AbbVie’s phase 2 study demonstrates how upadacitinib reduces type 1 inflammation and boosts melanocyte biomarkers to drive vitiligo response.

The analyzed dataset included over 200,000 patients with vitiligo to find trends in diagnosis, treatment, and more.

Serota and other field experts discussed best practices as well as new therapeutics.

Findings suggest that this novel treatment approach can enhance the quality of life for vitiligo patients without increasing the risk of adverse events.

A study found that vitiligo patients had a higher incidence of COVID-19 than those with psoriasis or atopic dermatitis.

Each treatment saw very mild clinical and dermatologic responses with low levels of patient satisfaction.

In his presentation at Winter Clinical Miami, Del Rosso covered a variety of topics including refractory pediatric vitiligo.

Emerging noninvasive imaging technologies, particularly optical coherence tomography, offer a revolutionary approach to monitoring vitiligo treatment responses.

Although more evidence is needed, CNNs could potentially be most effective in diagnosing patients with vitiligo.

Repibresib’s localized delivery minimizes systemic exposure while targeting inflammatory pathways, a novel approach for vitiligo management.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in vitiligo this year.

Karan Lal, DO; Lisa Swanson, MD; James Song, MD; Andrew Alexis, MD, MPH; and Lawrence Eichenfield, MD, discussed the complexities of vitiligo care and the potential of innovative topical therapies.

Researchers emphasized the need for future studies to refine protocols and address economic barriers to combination therapy.

2024 saw significant progress in vitiligo treatments, including novel drugs, off-label uses, and updated pediatric guidelines for better outcomes.

James Song, MD, discusses how recent advances in vitiligo treatment, including Janus kinase inhibitors and targeted immunotherapies, are transforming the therapeutic landscape with more effective options for repigmentation and disease management.

Explore key insights and innovations in vitiligo from 2024, from treatment advances to patient-focused strategies.

LOV has unique clinical traits, epidemiology, and treatment responses compared to early-onset vitiligo, underscoring the need for a tailored management approach.

Regenerative methods such as cell therapy and platelet-rich plasma showed promising results in patient repigmentation.

Learn more about the in-depth topics covered in the November 2024 AD and Vitiligo supplement of Dermatology Times.

Andrew Alexis, MD, MPH, discusses how, in creating individualized treatment plans for vitiligo, clinicians must carefully consider the distinct challenges and response patterns associated with segmental vs nonsegmental forms, as segmental vitiligo tends to be more stable after initial progression but often more resistant to treatment, while nonsegmental vitiligo typically shows a more unpredictable course requiring ongoing management strategies.

The panelist discusses the primary challenges in vitiligo repigmentation, including maintaining patient compliance through lengthy treatment courses and managing expectations around partial repigmentation outcomes, which require careful monitoring and ongoing patient education about realistic goals while assessing success through standardized documentation of even minimal improvements to inform treatment adjustments.

Andrew Alexis, MD, MPH, discusses how holistic management of vitiligo requires addressing both the physical and psychological impact through empathetic counseling and support groups while setting realistic treatment expectations and timelines with patients through clear communication about repigmentation goals, potential outcomes, and available therapeutic options.

Lisa Swanson, MD, discusses how telemedicine and digital health tools can aid in the management and follow-up care of pediatric patients with vitiligo by enabling remote monitoring, improving access to specialists, and facilitating patient engagement, while emerging research into vitiligo treatments may focus on developing therapies to halt or slow the progression of this autoimmune skin condition.

The panelist discusses advances in targeted therapies, including novel biologics and small molecules, as well as the development of personalized treatment approaches tailored to individual patient characteristics, which hold great promise for improving outcomes and enhancing the quality of life for children living with vitiligo in the future.